Experts delve into practical aspects of using elacestrant in later-line treatment of patients with estrogen receptor–positive (ER+)/HER2-negative (HER2–) metastatic breast cancer, including testing for ESR1 mutations, evaluating efficacy, and monitoring for toxicity.
This is a video synopsis/summary of a Peer Exchange featuring Mabel Mardones, MD; Rena Callahan, MD; William Gradishar, MD; and Gregory Vidal, MD, PhD.
Mardones explores practical considerations for elacestrant with Callahan, Gradishar, and Vidal. The discussion covers challenges in testing patients in later lines of therapy, uncertainties in treating those with both ESR1 and PI3 kinase mutations, and the evolving prevalence of ESR1 mutations over time.
The segment also delves into the efficacy of elacestrant, with Gradishar discussing response rates and progression-free survival. Notably, real-world experiences align with trial results, highlighting the drug’s tolerability.
This concise summary provides practical insights into incorporating elacestrant into clinical practices, considering testing challenges, and aligning trial outcomes with real-world scenarios.
Video synopsis is AI-generated and reviewed by AJMC® editorial staff.
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Study Highlights Significant Increases in Utilization, Spending on DMD Drugs in Medicaid
May 17th 2024The findings add to recent research on the growing utilization, expenditure, and prices of Duchenne muscular dystrophy (DMD) therapies in the current landscape, an area health care policy could potentially address.
Read More